NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations

Status: Open to Accrual

Learn More: 

• Clinicaltrials.gov: #NCT05498272

Study Contact: studies@hoosiercancer.org; (317) 921-2050.